150 related articles for article (PubMed ID: 1302039)
21. Clinical pharmacology of old and new antiarrhythmic drugs.
Siddoway LA; Roden DM; Woosley RL
Cardiovasc Clin; 1985; 15(3):199-248. PubMed ID: 2870805
[TBL] [Abstract][Full Text] [Related]
22. Metabolites of cardiac antiarrhythmic drugs: their clinical role.
Kates RE
Ann N Y Acad Sci; 1984; 432():75-89. PubMed ID: 6441496
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Rogers JF; Nafziger AN; Bertino JS
Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
[TBL] [Abstract][Full Text] [Related]
24. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
Kreeger RW; Hammill SC
Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs.
Woosley RL; Roden DM
Am J Cardiol; 1987 Apr; 59(11):19E-25E. PubMed ID: 3554949
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
Turgeon J; Evans WE; Relling MV; Wilkinson GR; Roden DM
Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
[TBL] [Abstract][Full Text] [Related]
27. Therapy with investigational antiarrhythmic drugs.
Mead RH; Harrison DC
Med Clin North Am; 1984 Sep; 68(5):1321-37. PubMed ID: 6436596
[TBL] [Abstract][Full Text] [Related]
28. Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides.
Botsch S; Heinkele G; Meese CO; Eichelbaum M; Kroemer HK
Eur J Clin Pharmacol; 1994; 46(2):133-5. PubMed ID: 8039531
[TBL] [Abstract][Full Text] [Related]
29. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.
Kroemer HK; Eichelbaum M
Life Sci; 1995; 56(26):2285-98. PubMed ID: 7791516
[TBL] [Abstract][Full Text] [Related]
30. Managing geriatric arrhythmias, II: Drug selection and use.
Lynch RA; Horowitz LN
Geriatrics; 1991 Apr; 46(4):41-4, 49-52, 54. PubMed ID: 2010094
[TBL] [Abstract][Full Text] [Related]
31. Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment.
Nestico PF; Morganroth J
Cardiol Clin; 1986 May; 4(2):285-303. PubMed ID: 3085932
[TBL] [Abstract][Full Text] [Related]
32. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
Jorge LF; Arias TD
Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
[TBL] [Abstract][Full Text] [Related]
33. Antiarrhythmic drug therapy. Recent advances and current status.
Somberg J
Cardiology; 1985; 72(5-6):329-48. PubMed ID: 2866841
[TBL] [Abstract][Full Text] [Related]
34. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
Blankson EA; Ellis SW; Lennard MS; Tucker GT; Rogers K
Biochem Pharmacol; 1991 Dec; 42 Suppl():S209-12. PubMed ID: 1768279
[No Abstract] [Full Text] [Related]
35. Topical beta-adrenergic antagonists and quinidine. A risky interaction.
Higginbotham EJ
Arch Ophthalmol; 1996 Jun; 114(6):745-6. PubMed ID: 8639090
[No Abstract] [Full Text] [Related]
36. Update: cardiac antiarrhythmic drugs.
Liem LB; Kates RE
Compr Ther; 1989 Apr; 15(4):17-27. PubMed ID: 2495883
[TBL] [Abstract][Full Text] [Related]
37. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
[TBL] [Abstract][Full Text] [Related]
38. Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6--a preliminary report.
Vandamme N; Broly F; Libersa C; Courseau C; Lhermitte M
J Cardiovasc Pharmacol; 1993 Jan; 21(1):77-83. PubMed ID: 7678683
[TBL] [Abstract][Full Text] [Related]
39. Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine.
Labbé L; Abolfathi Z; Lessard E; Pakdel H; Beaune P; Turgeon J
Xenobiotica; 2003 Jan; 33(1):13-25. PubMed ID: 12519691
[TBL] [Abstract][Full Text] [Related]
40. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
